Further decreased cell proliferation, as seen by decreased Ki67 and PCNA levels (Supplemental Figure 9, A–C) and increased apoptosis, as observed by the enhanced TUNEL positivity (Supplemental Figure 9, D and E), was observed in tumors that had received the dual treatment (CPT and C3, C7, and C17), thus demonstrating the importance of disruption of RAD54-BLM interaction in enhancing the therapeutic response to frontline chemotherapeutic drugs used for the treatment of colon cancer. The gene discussed is ATRX; the disease is malignant colon neoplasm.